Radioresistance in Glioblastoma and the Development of Radiosensitizers.

Autor: Ali MY; Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA 52242, USA.; Free Radical & Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.; Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA., Oliva CR; Free Radical & Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.; Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA., Noman ASM; Department of Biochemistry and Molecular Biology, The University of Chittagong, Chittagong 4331, Bangladesh.; Department of Pathology, McGill University, Montreal, QC H3A 2B4, Canada., Allen BG; Free Radical & Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.; Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA., Goswami PC; Free Radical & Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.; Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA., Zakharia Y; Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA., Monga V; Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA., Spitz DR; Free Radical & Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.; Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA., Buatti JM; Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA., Griguer CE; Free Radical & Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.; Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2020 Sep 03; Vol. 12 (9). Date of Electronic Publication: 2020 Sep 03.
DOI: 10.3390/cancers12092511
Abstrakt: Ionizing radiation is a common and effective therapeutic option for the treatment of glioblastoma (GBM). Unfortunately, some GBMs are relatively radioresistant and patients have worse outcomes after radiation treatment. The mechanisms underlying intrinsic radioresistance in GBM has been rigorously investigated over the past several years, but the complex interaction of the cellular molecules and signaling pathways involved in radioresistance remains incompletely defined. A clinically effective radiosensitizer that overcomes radioresistance has yet to be identified. In this review, we discuss the current status of radiation treatment in GBM, including advances in imaging techniques that have facilitated more accurate diagnosis, and the identified mechanisms of GBM radioresistance. In addition, we provide a summary of the candidate GBM radiosensitizers being investigated, including an update of subjects enrolled in clinical trials. Overall, this review highlights the importance of understanding the mechanisms of GBM radioresistance to facilitate the development of effective radiosensitizers.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje